News & Announcements

  • Director/PDMR Dealing

    /**/ RNS Number : 4320Q Imaging Biometrics Limited 09 July 2025   Imaging Biometrics Limited (“IB” or the “Company”)   PDMR dealing   Imaging Biometrics Limited, a leader in quantitative imaging solutions and novel therapies for CNS malignancies, announces that it has been notified of the following transactions in ordinary shares in the Company undertaken…

    Read more . . .

  • IB Provides Update on BTD Application

    /**/ RNS Number : 5919M Imaging Biometrics Limited 12 June 2025   Imaging Biometrics, Ltd (“IB” or the “Company”)   Imaging Biometrics Provides Update on Breakthrough Therapy Designation Application   Imaging Biometrics, Ltd, a leader in quantitative imaging solutions and novel therapies for CNS malignancies, today announces that following recent dialogue with the U.S. Food…

    Read more . . .

  • Change of Name

    /**/ RNS Number : 1221K Imaging Biometrics Limited 27 May 2025     Imaging Biometrics Limited (“IB” or the “Company”)   Change of Name   The Company is pleased to announce that, further to the announcement made on 29 April 2025, the Company has now formally changed its name from IQ-AI Ltd to Imaging Biometrics Ltd at…

    Read more . . .

  • Result of AGM

    /**/ RNS Number : 8413J IQ-AI Limited 22 May 2025     IQ-AI Limited (“IQ-AI” or the “Company”)   Result of AGM   IQ-AI Limited announces that at the annual general meeting of the Company held earlier today, all resolutions were duly passed.   For information, the proxy votes received prior to the meeting were…

    Read more . . .

  • Application: FDA Breakthrough Therapy Designation

    /**/ RNS Number : 2234H IQ-AI Limited 02 May 2025   IQ-AI Ltd (“IQ-AI” or the “Company”)   Imaging Biometrics Applies for FDA Breakthrough Therapy Designation May 2, 2025 – Imaging Biometrics, LLC (IB), a wholly owned subsidiary of IQ-AI Ltd (LSE: IQAI), has today applied to the U.S. Food and Drug Administration for ‘Breakthrough…

    Read more . . .

TOP